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Introduction
The epithelial component of normal and noninvasive
breast tumor tissue is physically separated from the
stroma by both the myoepithelial cells and the basement
membrane (BM). Myoepithelial cells are joined by interme-
diate or gap junctions and a number of intercellular adhe-
sion molecules, forming a continuous sheet or belt that
encircles the epithelial cells (except at the terminal
ductal–lobular unit, within which about 20% of the epithe-
lial cells are reported to be in direct contact with the BM)
BM = basement membrane; DCIS = ductal carcinoma in situ; ER = estrogen receptor; H & E = hematoxylin and eosin; LOH = loss of heterozygosity;
MI = microsatellite instability; PCR = polymerase chain reaction; SMA = smooth muscle actin.
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Abstract
Introduction Our previous studies detected focal disruptions
in myoepithelial cell layers of several ducts with carcinoma in
situ. The cell cluster overlying each of the myoepithelial
disruptions showed a marked reduction in or a total loss of
immunoreactivity for the estrogen receptor (ER). This is in
contrast to the adjacent cells within the same duct, which
were strongly immunoreactive for the ER. The current study
attempts to confirm and expand previous observations on a
larger scale.
Methods Paraffin sections from 220 patients with ER-positive
intraductal breast tumors were double immunostained with the
same protocol previously used. Cross-sections of ducts lined
by  ≥40 epithelial cells were examined for myoepithelial cell
layer disruptions and for ER expression. In five selected cases,
ER-negative cells overlying the disrupted myoepithelial cell
layer and adjacent ER-positive cells within the same duct were
separately microdissected and assessed for loss of hetero-
zygosity and microsatellite instability.
Results Of the 220 cases with 5698 duct cross-sections
examined, 94 showed disrupted myoepithelial cell layers with
405 focal disruptions. Of the 94 cases, 79 (84%) contained
only ER-negative cell clusters, nine (9.6%) contained both ER-
negative and ER-positive cell clusters, and six (6.4%) contained
only ER-positive cell clusters overlying disrupted myoepithelial
cell layers. Of the 405 disruptions, 350 (86.4%) were overlain
by ER-negative cell clusters and 55 (13.6%) were overlain by
ER-positive cell clusters (P<0.01). Microdissected ER-negative
and ER-positive cells within the same duct from all five selected
cases displayed a different frequency or pattern of loss of
heterozygosity and/or microsatellite instability at 10 of the
15 DNA markers.
Conclusions Cells overlying focally disrupted myoepithelial
layers and their adjacent counterparts within the same duct
displayed different immunohistochemical and molecular
features. These features potentially represent an early sign of
the formation of a biologically more aggressive cell clone and
the myoepithelial cell layer breakdown possibly associated with
tumor progression or invasion.
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[1–3]. The BM is composed of a group of fibrous proteins
embedded in a hydrated polysaccharide gel, constituting a
continuous lining surrounding and attaching to myoepithe-
lial cells via hemidesmosomes and focal adhesion com-
plexes [3–5]. Both the myoepithelial cell layer and the BM
layer are permanent structural constituents, normally allow-
ing only the passage of small molecules [1–5]. Due to this
structural feature, most tumor epithelial cells have to first
pass through the myoepithelial cell layer and then the BM
in order to physically contact the stroma. In other words,
the disruption of both the BM and the myoepithelial cell
layer is an absolute prerequisite for breast tumor invasion.
Invasive and metastasized tumors, compared with in situ
tumors, have a significantly higher mortality rate, account-
ing for a vast majority of breast cancer death [6]. This
highlights the significance and the implications for the elu-
cidation of the tumor invasion mechanism(s), which could
potentially lead to vast benefits and advances in the field
of breast cancer treatment and prevention. It has been
generally accepted that an upregulated expression of pro-
teolytic enzymes in tumor or stromal cells is the primary, if
not the only, cause for BM disruptions and tumor invasion
[6,7]. This theory, however, might not reflect the intrinsic
mechanism(s) of myoepithelial layer disruptions for three
main reasons. First, neither the normal cellular kinetics nor
dynamic alterations of myoepithelial cells during tumor
invasion have been well elucidated. Also, no conclusive
evidence has shown that the host’s own enzymes are
capable of degrading its own myoepithelial cells. Finally,
the results of proteolytic inhibitor-based human clinical
trials for breast cancer treatment and prevention have
been very disappointing [8].
While attempting to identify the early sign of myoepithelial
disruptions and the precursor of invasion, we have carried
out a number of studies focusing on the physical and func-
tional correlation between epithelial and surrounding
myoepithelial cells. In one of our previous studies, a
double immunostaining method with antibodies to smooth
muscle actin (SMA) and to the estrogen receptor (ER)
was used to elucidate both epithelial cells and myoepithe-
lial cells [9]. Several focal myoepithelial cell layer disrup-
tions, defined as a total loss of SMA immunoreactivity and
an absence of myoepithelial cells, resulting in a gap that is
equal to or greater than the combined size of at least three
epithelial or myoepithelial cells, were detected in several
ducts that were classified as ductal carcinoma in situ
(DCIS) based on examination on H&E stained slides.
Each of the disruptions was exclusively overlain by a
cluster of cells that showed either a complete loss of or a
marked reduction of ER expression, in contrast to the
adjacent nondisrupted myoepithelial cell layer within the
same duct, which was overlain by cells with strong ER
expression [9]. Those ER-negative cell clusters and focal
myoepithelial disruptions, however, were generally small
and not easily identifiable on H&E stained sections [9].
Our subsequent studies further revealed that ducts with a
disrupted myoepithelial cell layer had a significantly higher
proliferation rate than ducts with an intact myoepithelial
layer [10,11].
It has been documented that the disruption of the BM and
myoepithelial cell layers is an absolute prerequisite for tumor
invasion, that tumor epithelial cells and their surrounding
stromal cells share a similar genetic profile [12,13], and that
the progression of breast tumors is paralleled by a progres-
sive hormonal independence [14–17]. Our findings there-
fore appear to have several clinical implications. First, those
ER-negative cell clusters overlying the disrupted myoepithe-
lial cell layer may represent a newly formed cell clone that is
biologically more aggressive than the adjacent ER-positive
cells within the same duct. Second, focal myoepithelial cell
layer disruption might represent an initial or early sign of the
BM and myoepithelial cell layer breakdown. Third, focal dis-
ruptions in the myoepithelial cell layer and the loss of ER
expression in overlying cells might be correlated events,
directly triggering or signifying tumor progression or poten-
tial invasion in some cases.
Based on these speculations, the present study attempted
to confirm our previous observations in a larger number of
cases, to determine whether focal disruptions of myo-
epithelial cell layers is a prevalent event, and whether all
the cell clusters overlying focally disrupted myoepithelial
cell layers have the same morphological and immunostain-
ing feature. Also, we attempted to carry out a preliminary
molecular study to compare the frequency and pattern of
loss of heterozygosity (LOH) and microsatellite instability
(MI) between ER-negative cells and the adjacent ER-
positive cells within the same duct in selected cases.
Materials and methods
Formalin-fixed, paraffin-embedded breast tissue blocks
harboring various grades and subtypes of ER-positive,
noninvasive breast lesions from 220 female patients were
retrieved from the files of The Armed Forces Institute of
Pathology. Serial sections of 5–7µm thickness were cut
and placed on positively charged microscopic slides for
immunohistochemical and morphologic assessment. Mor-
phologic classifications were based on our published cri-
teria [9]. Double immunohistochemical staining with
antibodies to the ER (clone 6F11) and to SMA (clone
asm-1) (Vector Laboratories, Burlingame, CA, USA) was
carried out as previously described [9,18,19]. A micro-
meter was inserted into the objective of a microscope to
facilitate the reviewing of the whole section and the local-
ization of a specific lesion [20].
Cross-sections of ducts lined by ≥40 epithelial cells were
examined under a microscope for myoepithelial cell layer
disruptions and for ER expression. A focal myoepithelialR233
layer disruption was defined as a total loss of SMA
immunoreactivity and an absence of myoepithelial cells,
resulting in a gap that is equal to or greater than the com-
bined size of at least three epithelial or myoepithelial cells,
or multiple such gaps in a given duct. A focal loss of ER
expression was defined as a total loss or a marked reduc-
tion of ER immunostaining in cells overlying disrupted
myoepithelial cell layers, compared with a strong ER
immunostaining in their adjacent counterparts within the
same duct overlying the nondisrupted myoepithelial cell
layer. A focal positive ER expression was defined as the
ER immunostaining in cells overlying focally disrupted
myoepithelial cell layers being more intense than or com-
parable to that in their adjacent counterparts overlying the
nondisrupted myoepithelial cell layer.
The profiles of ducts containing disrupted myoepithelial
cell layers were photographed and reprints were made at
a magnification of 400×–800× for immunohistochemical
and morphological evaluation. The frequencies of myo-
epithelial cell layer disruptions associated with ER-nega-
tive and ER-positive cell clusters were statistically
compared by the Student t test.
The adjacent sections from 20 cases with focal myo-
epithelial disruptions were immunostained with mono-
clonal antibodies to cytokeratins AE1/AE3 (clones
AE1/AE3; Chemicon, Temecula, CA, USA), to
cytokeratin 8 (clone TS1; Vector Laboratories), and to
cytokeratin 19 (clone b170; Vector Laboratories) in order
to assess whether cells overlying disrupted myoepithelial
cell layers are epithelial in nature [21]. Also, the sections
in selected cases were immunostained with antibodies to
major constituents of the BM-collagen IV (clone CIV 22;
Dako Corporation, Carpinteria, CA, USA) and laminin
(code number Z0097; Dako Corporation; and clone
Lam-89; Vector Laboratories) to assess the integrity of the
BM underneath the disrupted myoepithelial cell layers.
For molecular analyses, paired ER-negative cells and adja-
cent ER-positive cells within the same duct, along with
clear-cut normal epithelial or stromal cells, were microdis-
sected from each of five selected cases, including one
mild ductal hyperplasia and four DCIS or atypical intraduc-
tal hyperplasia. To obtain a sufficient number of cells, mul-
tiple consecutive sections were immunostained, and
ER-negative cell clusters in different sections were
microdissected and pooled. Microdissected cells were
subjected to DNA extraction and assessed for LOH and
for MI with 15 fluorescent-labeled DNA markers (Research
Genetics, Huntsville, AL, USA) as previously described
[22]. The DNA markers used and their main features are
presented in Table 1. Amplified PCR products were sub-
jected to electrophoresis, detection, and comparison with
an automated 377 DNA sequencer (Perkin-Elmer, Foster
City, CA, USA) as previously described [23,24].
Results
Of the 220 cases, 14 (6.4%) contained less than three
profiles and 206 (93.6%) contained more than three pro-
files of duct cross-sections, with a total of 5698 profiles
available for assessment. Of the total cases and cross-
sections examined, 94 (42.7%) cases contained a dis-
rupted myoepithelial cell layer with a total of 405 (7.1%)
focal disruptions. Of the 94 cases, 61 (65%) contained
one to four disruptions, and 33 (35%) contained five or
more disruptions. Disruptions occurred in two forms: a
cell-free gap between the two ends of the myoepithelial
cell layer, and/or a gap filled with bud-like protrusions of
epithelial cells. The size of disruptions varied substantially
among ducts, ranging from the combined size of three to
more than 30 myoepithelial cells. The frequency of disrup-
tions also varied substantially among cases. In two cases
that contained 129 and 130 profiles of duct cross-
sections, respectively, no disruption was seen. In another
two cases, two of two profiles and five of the seven pro-
files demonstrated focal myoepithelial layer disruptions.
The form, size, or frequency of disruptions seemed to be
independent of the size, length, architecture, and overall
ER negativity of the ducts, and also of the histological
grade of the lesions (Fig.1).
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Table 1
DNA markers used for comparison of genetic alterations in
estrogen receptor-negative cells and estrogen receptor-
positive cells
Chromosomal Size
Marker Name location Harbored gene (base pairs)
1 D3S1300 3p21.1–p14.2 FHIT 217–241
2 D3S1481 3p14.2 FHIT 104
3 D3S1581 3p21.2–p14.2 FHIT 78–102
4 D11S902 11p15–p13 ? 145–163
5 D11S904 11p14–p13 Wilms’ tumor 1 185–201
6 D11S907 11p13 Wilms’ tumor 1 163–173
7 D11S914 11p13–p12 Wilms’ tumor 1 275–285
8 D13S119 13q14.3–q22 ? 124–140
9 D13S173 13q32–q34 ? 166–178
10 D13S219 13q12.3–q13 ? 117–127
11 D13S263 13q14.1–q14.2 ? 145–165
12 D16S518 16q23.1–q24.2 CDH 1 272–290
(adjacent to it)
13 D16S402 16q24.2 CDH 1 161–187
(adjacent to it)
14 D17S791 17q BRCA 1 165–199
15 TP53 17p13 P53 104
FHIT, fragile histidine triad.The frequency and pattern of myoepithelial cell layer dis-
ruptions, however, were closely associated with the ER
expression status in overlying cells. Of the 94 cases, 79
(84%) contained only ER-negative cell clusters, nine
(9.6%) contained both ER-negative and ER-positive cell
clusters, and six (6.4%) contained only ER-positive cell
clusters overlying the disrupted myoepithelial cell layers.
Of the 405 disruptions, 350 (86.4%) were overlain by ER-
negative cell clusters and 55 (13.6%) were overlain by
ER-positive cell clusters (Table 2). The frequency of
myoepithelial cell layer disruptions associated with
ER-negative cells was significantly higher (P<0.01) than
that associated with ER-positive cells. The number of ER-
negative cells overlying the disrupted myoepithelial cell
layer varied markedly, ranging from three to more than
100 cells. These cells were generally distributed as clus-
ters, and cells of the same cluster were morphologically
similar. A vast majority (>90%) of the ER-negative cell
clusters were small (<15 cells) and not easily appreciable
on H&E stained sections (Fig.2). The ER-negative cells in
some of the larger clusters (>15 cells), however, showed
noticeable alterations in shape and density, morphologi-
cally distinct from their adjacent ER-positive counterparts
within the same duct (Fig.3). More than 95% of the ducts
contained only one or two disruptions, while a few of the
ducts displayed multiple disruptions in the myoepithelial
cell layer (Fig.4). The stromal tissues surrounding ducts
with myoepithelial cell layer disruptions were often more
vascular and contained more leukocyte aggregates, com-
pared with stromal tissues surrounding ducts with an
intact myoepithelial cell layer (data not shown).
Although more than 86% of the myoepithelial cell layer
disruptions were overlain by ER-negative cell clusters,
nearly 14% of the disruptions were subjacent to ER-posi-
tive cell clusters. These ER-positive clusters were gener-
ally distinct from ER-negative cell clusters in three
aspects: most of the clusters occurred in ducts with
markedly attenuated myoepithelial cell layers, they usually
showed no alterations in cell shape, density, or polarity,
and the surrounding stromal tissues displayed no distinct
morphological alterations (Fig.5).
The myoepithelial cell layer disruptions and their associ-
ated ER-negative cell clusters occurred in ducts with
DCIS or atypical intraductal hyperplasia in 90.6% of the
cases. In 9.4% of the cases, however, myoepithelial cell
layer disruptions and associated ER-negative cell clusters
Breast Cancer Research    Vol 5 No 6 Man et al.
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Figure 1
Disruptions of myoepithelial cell layers are independent of the size,
length, architecture, and overall estrogen receptor (ER) negativity of
the ducts. Paraffin-embedded breast tissue sections were double
immunostained with antibodies to ER and smooth muscle actin, and
were developed with 3,3′-diaminobenzidine (DAB; black or brown) and
3-amino-9-ethylcarbazole (AEC; red) chromogens, respectively.
Distinct myoepithelial cell layers are seen in the following structures:
(a) a large duct with ductal carcinoma in situ (DCIS), 100×; (b) a long
normal duct, 40×; (c) a duct with intraductal hyperplasia, 100×; 
(d) intermediate grade ER-negative DCIS, 100×.
Table 2
Frequency of myoepithelial cell layer disruptions and the status of estrogen receptor expression
Total cross-sections Total disruptions Focal loss of estrogen receptor Estrogen receptor-positive P
5698 405 (7.1%) 350 (86.4%) 55 (13.6%) < 0.01were seen in hyperplastic, and even normal appearing,
ducts (Fig.6).
All the ER-negative cell clusters overlying the disrupted
myoepithelial cell layer and their adjacent ER-positive
counterparts in all 20 cases showed distinct immunoreac-
tivity to cytokeratin 8, cytokeratin 19, and cytokeratins
AE1/AE3, suggesting that they are epithelial in nature
(data not shown). Immunostaining with antibodies to colla-
gen IV and laminin revealed no distinct immunoreactivity
surrounding disrupted myoepithelial cell layers, suggest-
ing that the basement membrane was also disrupted (data
not shown). The ER-negative cell clusters were either in or
protruded from the epithelial component.
Molecular analyses on microdissected cells from the five
selected cases revealed distinct LOH and MI in both
ER-negative cells and adjacent ER-positive cells within the
Available online http://breast-cancer-research.com/content/5/6/R231
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Figure 2
Myoepithelial cell layer disruptions and overlying small estrogen
receptor (ER)-negative cell clusters (<15 cells) in ER-positive ductal
carcinoma in situ (DCIS). (a) H & E staining of a large duct with DCIS,
100×; (b) the adjacent section of (a) immunostained, 100×; (c) a
higher magnification of (a); (d) a higher magnification of (b). The
myoepithelial cell layer disruption and the overlying ER-negative cells
are identified with an arrow.
Figure 3
Myoepithelial cell layer disruptions and overlying larger estrogen
receptor (ER)-negative cell clusters (>15 cells) in ER-positive
neoplastic and hyperplastic ducts. All sections were immunostained for
ER (brown) and smooth muscle actin (red). (a) Ductal carcinoma in
situ, 100×; (b) two small ducts with atypical intraductal hyperplasia,
100×; (c) a hyperplastic duct, 100×; (d) two hyperplastic ducts,
200×. Myoepithelial cell layer disruptions and ER-negative cell clusters
are identified with arrows.same duct at each of the 15 DNA markers. The frequency
of LOH and MI among the DNA markers, however, varied
from 12% to more than 70%. The ER-negative and
ER-positive cells showed a different frequency or pattern
of LOH and MI at 10 of the 15 markers, including those at
chromosomes 3p, 11p, 13q, and 16q. Figure 7 shows
examples of the LOH pattern in ER-negative cells and
adjacent ER-positive cells from a selected case. Subse-
quently, and currently, additional cases with ER-negative
cell clusters overlying disrupted myoepithelial cell layers
were selected for a larger scale comparison at a wider
spectrum. The preliminary results are in agreement with
those seen in the five previously selected cases. The
detailed findings in all these cases will be pooled and
reported separately.
Discussion
The myoepithelial cell layer has been traditionally regarded
as a structural barrier for separating mammary epithelial
cells from the surrounding stroma and for contracting
ductal and lobular spaces assisting milk secretion [25,26].
Recent studies, however, have revealed several lines of
evidence suggesting that myoepithelial cells may play
active roles in preventing in situ tumors from invasion, and
in regulating the functions of the epithelial cells.
First, normal myoepithelial cells secrete several cell growth
inhibitors, including maspin, which inhibit tumor cell growth
in both tissue cultures and in animal models [27–29].
Second, normal myoepithelial cells can convert precursor
hormones into active steroid hormones within the
mammary epithelial tissue [30]. Third, the protein of a
tumor suppressor gene, Wilms’ tumor 1, is colocalized with
maspin exclusively in myoepithelial cells, and the expres-
sion of these two proteins is linearly decreased with tumor
progression in a vast majority of the cases assessed
[10,11]. The loss of maspin and Wilms’ tumor 1 expression
or the disruption of myoepithelial cell layers leads to a sig-
nificantly higher epithelial cell proliferation [10,11].
On the other hand, recent studies have suggested that
myoepithelial cells could be the specific target of external
and internal insults and could be subject to a variety of
normal and pathologic changes. The exposure to lambda
carrageenan could specifically result in the filament disas-
sembly and loss of the mammary myoepithelial cells,
whereas exposure to oxytocin could markedly enhance the
myoepithelial cell differentiation and proliferation [31,32].
Our recent study has further demonstrated a subset of
myoepithelial cells that are morphologically distinct on
H&E sections, but are devoid of expression of nine phe-
notypic markers that are supposed to be exclusively or
preferentially expressed in myoepithelial cells [33].
Despite this recent progress in myoepithelial cell research,
the cell kinetics of myoepithelial cells has not been eluci-
dated, and the mechanism of myoepithelial cell layer dis-
ruptions remains elusive.
Based on our recent findings, we hypothesize that disrup-
tions of the BM and myoepithelial cell layers and tumor
invasion may be initiated or mediated by myoepithelial
cells. Our hypothesized mechanism and the involved
processes are as follows. Normal myoepithelial cells fre-
quently undergo proliferation and differentiation to replace
Breast Cancer Research    Vol 5 No 6 Man et al.
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Figure 4
Multiple myoepithelial cell layer disruptions and overlying estrogen
receptor (ER)-negative cell clusters in ductal carcinoma in situ. (a) A
paraffin section immunostained for ER (brown) and smooth muscle
actin (SMA) (red), 200×; (b) a higher magnification of (a), 400×; (c) a
paraffin section immunostained for ER (brown) and SMA (red), 200×;
(d) a higher magnification of (c), 400×. Myoepithelial cell layer
disruptions and ER-negative cell clusters are identified with arrows.aged or injured cells. An external or internal insult then dis-
rupts the normal replacement process, resulting in a
cluster of dying myoepithelial cells. Following this,
degraded products of dead myoepithelial cells attract lym-
phocyte infiltration that physically disrupts the BM. A focal
disruption in the myoepithelial cell layer and the BM layer
then results in an increased permeability for metabolism-
and growth-related molecules. The altered micro-environ-
ment results in the changes of the gene expression
pattern and the behavior of the adjacent epithelial cells,
Available online http://breast-cancer-research.com/content/5/6/R231
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Figure 5
Myoepithelial cell layer disruptions and associated estrogen receptor (ER)-positive cells in hyperplastic ducts. All sections were immunostained
immunostained for ER (brown) and smooth muscle actin (red). (a), (b) Two ER-positive hyperplastic ducts showing attenuated and disrupted
myoepithelial cell layers, 200×. The disruptions are identified with arrows.
Figure 6
Myoepithelial cell layer disruptions and overlying estrogen receptor (ER)-negative cell clusters in normal and hyperplastic appearing ducts. All
sections were immunostained immunostained for ER (brown) and smooth muscle actin (red). (a)–(c) Normal appearing ducts, 400×; (d)–(f)
hyperplastic ducts, 400×. Myoepithelial cell layer disruptions and ER-negative cell clusters are identified with arrows.facilitating the formation of a biologically more aggressive
cell clone. Epithelial cells overlying disrupted myoepithelial
cell layers then undergo a localized epithelial cell prolifera-
tion, which may occur in two forms: stem cell mediated
proliferation that gives rise to ER-negative cell clusters,
and differentiated cell mediated proliferation that produces
ER-positive cells. Finally, cells overlying disrupted myo-
epithelial cell layers undergo cytodifferentiation, releasing
stage-restricted and invasion-associated molecules, which
trigger angiogenesis, tissue remodeling, and increasing
production of growth factors in the stroma, providing a
favorable environment for epithelial cell growth [34–36].
These interactive changes between epithelial and stromal
cells lead to further degradation of the BM and myoepithe-
lial cell layers, and a clonal expansion and stromal invasion
of cells overlying disrupted myoepithelial cell layers.
Our hypotheses appear to be supported by the results of
two recent studies showing that the frequency of white
blood cell infiltration into the tumor tissues seems to lin-
Breast Cancer Research    Vol 5 No 6 Man et al.
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Figure 7
Comparison of the loss of heterozygosity (LOH) pattern in estrogen receptor (ER)-negative cells and adjacent ER-positive cells within the same
duct. (a) H & E staining of a duct with atypical intraductal hyperplasia, 200×; (b) the adjacent section of (a) immunostainined (before
microdissection), 200×; (c) microdissection of ER-positive cells; (d) microdissection of ER-negative cells; (e) LOH at four selected DNA markers.
Asterisks indicate the ER-negative cells and the ER-positive cells removed; arrows identify LOH.early increase with tumor progression [37,38]. Our
hypotheses are also in an agreement with the results of
our most recent study, which reveals that ducts with
focally disrupted myoepithelial cell layers have a signifi-
cantly higher rate of white blood cell infiltration and more
clusters of multiple proliferating cells compared with mor-
phologically comparable ducts without myoepithelial dis-
ruptions (unpublished data). It is not known, however,
whether or to what extent our hypothesis reflects the
intrinsic mechanism of the BM and myoepithelial cell layer
disruptions. However, given the fact that the disruption of
the BM and myoepithelial cell layers is an absolute prereq-
uisite for tumor invasion, and that progression of breast
tumors is paralleled by a progressive hormonal indepen-
dence [14–17], our hypothesized model might open a
new window for exploring these issues.
The mechanism for the loss or diminution of ER expres-
sion in cells overlying a disrupted myoepithelial cell layer is
unknown, but could result from several reasons. First,
these cells might be in the status of actively proliferating.
A previous immunohistochemical study in human breasts
has shown that none of the epithelial cells with ER expres-
sion and progesterone receptor expression was proliferat-
ing, and none of the proliferating cells showed either ER
or progesterone receptor expression [39]. Second, the ER
gene in these cells might have been inactivated by methy-
lation during tumor progression. Previous studies have
shown that the progression of breast tumors is paralleled
by a progressive hormonal independence [14–17]. Third,
these cells might express a different type of ER, including
variants of the β-ER. A recent study has revealed that
α-ER and β-ER are separately localized in a subset of
breast tumors and appear to have different functions [40].
Fourth, these cells might be derived from the myoepithelial
lineage. A number of previous studies have shown that
myoepithelial cells can express partial myodifferentiation in
human breast cancer [41–43]. Finally, these cells are
newly formed through a stem cell mediated clonal prolifer-
ation and are not mature enough to express the ER
protein. Previous studies have demonstrated that the ER
expression status is related to the age or differentiation
status of the cells [25,44].
While each of these five assumptions could partially
explain the loss of ER expression in cell clusters overlying
disrupted myoepithelial cell layers, a stem cell mediated
clonal proliferation appears to be a more reasonable inter-
pretation, as our most recent studies on the same tissues
used in the current study have further revealed several
new features of these ER-negative clusters: negativity to
p-cadherin, a newly introduced specific myoepithelial cell
marker; strong immunoreactivities to epithelial-specific
antigen; lost or markedly reduced expression of p27, a cell
growth inhibitor; and a unique rate and pattern of cell pro-
liferation-related proteins [45,46]. It is also possible,
however, that these ER-negative clusters represent the
intermediate cells of a myoepithelial lineage, as our previ-
ous study has revealed that a subset of morphologically
distinct myoepithelial cells is devoid of the ER and also a
total of nine markers that are supposed to be exclusively
or preferentially expressed in myoepithelial cells [33]. In
any case, the loss or reduction of the ER, along with a dif-
ferent pattern of genetic alterations, suggests that the ER-
negative clusters and their adjacent ER-positive
counterparts may have substantially different genetic and
biochemical profiles. Consequently, comparisons of these
two cell populations at DNA, RNA, and protein levels may
lead to identification of very specific biomolecules that are
exclusively associated with myoepithelial cell layer disrup-
tions and tumor invasion. These molecules might be used
for development of vaccine or biomarkers for early detec-
tion, treatment, and prevention of breast cancer [47].
Conclusions
A total of 405 focal disruptions in the myoepithelial cell
layers were detected from 5698 duct cross-sections of 94
patients with DCIS. Of the 405 disruptions, 350 (86.4%)
were overlain by ER-negative cell clusters and 55 (13.6%)
were overlain by ER-positive cell clusters (P<0.01).
The microdissected ER-negative and ER-positive cells
within the same duct from all five selected cases showed
a different frequency or pattern of LOH and/or MI at 10 of
15 markers.
The loss or reduction of ER expression, along with a differ-
ent pattern of genetic alterations, suggests that the
ER-negative cell clusters and their adjacent ER-positive
counterparts might have substantially different genetic and
biochemical profiles.
Competing interests
None declared.
Acknowledgements
The opinions and assertions contained herein represent the personal
views of the authors and are not to be construed as official or as repre-
senting the views of the Department of the Army or the Department of
Defense. The authors are grateful to Doug Landry and James A Nola of
the Armed Forces Institute of Pathology exhibition section for their
technical assistance in preparing the figures. This study was supported
by The Congressionally Directed Medical Programs, grants DAMD 17-
01-0129 and DAMD17-01-0130 (to Y-gM).
References
1. Tsubura A, Shikata N, Inui T, Morii S, Hatano T, Oikawa T:
Immunohistochemical localization of myoepithelial cells and
basement membrane in normal, benign and malignant human
breast lesions. Virchows Arch 1988, 413:133-139.
2. Jolicoeur F, Seemayer TA, Gabbiani G, Robidoux A, Gaboury L,
Oligny LL, Schurch W: Multifocal, nascent, and invasive
myoepithelial carcinoma (malignant myoepithelioma) of the
breast: an immunohistochemical and ultrastructural study. Int
J Surg Pathol 2002, 10:281-291.
3. Slade MJ, Coope RC, Gomm JJ, Coombes RC: The human
mammary gland basement membrane is integral to the polar-
ity of luminal epithelial cells. Exp Cell Res 1999, 247:267-278.
Available online http://breast-cancer-research.com/content/5/6/R231
R2394. Miosge N: The ultrastructural composition of basement mem-
brane in vivo. Histol Histopathol 2001, 16:1239-1248.
5. Nerlich A: Morphology of basement membrane and associ-
ated matrix proteins in normal and pathological tissues. Veroff
Pathol 1995, 145:1-139.
6. Pasqualini JR: Breast Cancer—Prognosis, Treatment, and Preven-
tion. New York: Marcel Dekker; 2002.
7. Goldfarb RH, Liotta LA: Proteolytic enzymes in cancer invasion
and metastasis. Semin Thromb Hemost 1986, 12:294-307.
8. Coussens LM, Fingleton B, Matrisian LM: Matrix metallopro-
teinase inhibitors and cancer: trial and tribulations. Science
2002, 295:2387-2392.
9. Tavassoli FA, Man YG: Morphofunctional features of intraduc-
tal hyperplasia, atypical hyperplasia, and various grades of
intraductal carcinoma. Breast J 1995, 1:155-162.
10. Man YG, Saenger JS, Strauss BL, Vang RS, Bratthauer GL, Chen
PY, Tavassoli FA: Focal alterations of p27 expression and sub-
jacent myoepithelial cell layer disruptions are correlated
events in ER(–) ductal intraepithelial neoplasia. In Proceedings
of Department of Defense Breast Cancer Research Program
Meeting: September 25–28 2002; Orlando, FL, vol. 1. Fort
Detrick, MD: US Army Medical Research and Material Command;
2002: Poster section 9:14.
11. Man YG, Vang RS, Saenger JS, Strauss BL, Bratthauer GL, Chen
PY, Tavassoli FA: Co-expression of maspin and Wilms’ tumor 1
proteins in mammary myoepithelial cells: implication for
tumor progression and invasion. In Proceedings of Department
of Defense Breast Cancer Research Program Meeting: Septem-
ber 25–28 2002; Orlando, FL, vol. 1. Fort Detrick, MD: US Army
Medical Research and Material Command; 2002: Poster section
9:16.
12. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavas-
soli FA: Concurrent and independent genetic alterations in the
stromal and eoithelial cells of mammary carcinoma: implica-
tions for tumorigenesis. Cancer Res 2000, 60:2562-2566.
13. Man YG, Mannion C, Albores-Saaverdra J, Bratthauer GL, Kuhls
E, Tavassoli FA: Allelic losses at 3p and 11p are detected in
both epithelial and stromal components of cervical small cell
neuroendocrine carcinoma. Appl Immunohistochem Mol
Morphology 2001, 9:340-345.
14. Schmitt FC: Multistep progression from an oestrogen-depen-
dent growth towards an autonomous growth in breast car-
cinogenesis. Eur J Cancer 1995, 31A:2049-2052.
15. Clarke R, Brunner N, Katzenellenbogen BS: Progression of
human breast cancer cells from hormone-dependent to
hormone-independent growth both in vitro and in vivo. Proc
Natl Acad Sci USA 1989, 86:3649-3653.
16. Murphy LC: Mechanism of hormone independence in human
breast cancer. In vivo 1998, 2:95-106.
17. Sheikh MS, Garcia M, Pujol P, Fontana JA, Rochefort H: Why are
estrogen receptor negative breast cancers more aggressive
than the estrogen receptor positive breast cancers? Invasion
Metastasis 1994–95, 14:329-336.
18. Man YG, Tavassoli FA: A simple epitope retrieval method
without the use of microwave oven or enzyme digestion. Appl
Immunohistochem 1996, 4:139-141.
19. Man YG, Ball WD, Culp AJ, Hand AR, Moreira JE: Persistence of
a perinatal cellular phenotype in the ducts of adult glands.
J Histochem Cytochem 1995, 43:1203-1215.
20. Man YG, Schammel DP, Tavassoli FA: Detection of telomerase
activity in microdissected breast lesions [abstract]. Cell Vision
1998, 5:84-85.
21. Moinfar F, Man YG, Lininger RA, Tavassoli FA: Use of keratin
34β βE12 as an adjunct in the diagnosis of mammary intraepithe-
lial neoplasia—duct type (benign and malignant intraductal pro-
liferations of the breast). Am J Surg Pathol 1999, 23:1048-1058.
22. Man YG, Moinfar F, Bratthauer GL, Kuhls E, Tavassoli FA: An
improved method for DNA extraction from paraffin sections.
Pathol Res Prac 2001, 197:635-642.
23. Man YG, Moinfar F, Bratthauer GL, Tavassoli FA: Five useful
approaches for generating more valid gel images for LOH and
clonality analysis with an automated DNA sequencer. Diag
Mol Pathol 2000, 9:84-90.
24. Man YG, Kuhls E, Bratthauer GL, Moinfar F, Tavassoli FA: Multi-
ple use of slab gels in sequencing apparatus for separation of
polymerase chain reaction products. Electrophoresis 2001, 22:
1915-1919.
25. Robinson GW, McKnight RA, Smith GH, Hennighausen L:
Mammary epithelial cells undergo secretory differentiation in
cycling virgins but require pregnancy for the establishment of
terminal differentiation. Development (Camb) 1995, 121:2079-
2090.
26. Chodosh LA, Cruz CMD, Gardner HP: Mammary gland develop-
ment, reproductive history, and breast cancer risk. Cancer Res
1999, 59:1765s-1772s.
27. Sternlight MD, Barsky SH: The myoepithelial defense: a host
defense against cancer. Med Hypotheses 1997, 48:37-46.
28. Sternlight MD, Safarians S, Rivera SP, Barsky SH: Characteriza-
tion of the extracellular matrix and proteinase inhibitor
content of human myoepithelial tumors. Lab Invest 1996, 74:
781-796.
29. Shao ZM, Nguyen M, Alpaugh ML, O’Connell JT, Barsky SH: The
human myoepithelial cells exerts antiproliferative effects on
breast carcinoma cells characterized by p21WAF1/CIPI induc-
tion, G2M arrest, and apoptosis. Exp Cell Res 1998, 241:394-
403.
30. Tobacman JK, Hinkhouse M, Khalkhali-Ellis Z: Steroid sulfatase
activity and expression in mammary myoepithelial cells.
J Steroid Biochem Mol Biol 2002, 81:65-68.
31. Tobacman JK: Filament disassembly and loss of mammary
myoepithelial cells after exposure to lambda-carrageenan.
Cancer Res 1997, 57:2823-2826.
32. Sapino A, Macri L, Tonda L, Bussolati G: Oxytocin enhances
myoepithelial cell differention and proliferation in the mouse
mammary gland. Endocrinology 1993, 133:838-842.
33. Zhang R, Man YG, Vang RS, Saenger JS, Barner R, Wheeler DT,
Liang CY, Vinh TN, Bratthauer GL: A subset of morphologically
identifiable mammary myoepithelial cells lacks expression of
corresponding phenotypic markers. Breast Cancer Res 2003,
5:R151-R156.
34. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW: The
organizing principle: microenvironmental influences in the
normal and malignant breast. Differentiation 2002, 70:537-546.
35. Muschler J, Levy D, Boudreau R, Henry M, Campbell K, Bissell MJ:
A role for dystroglycan in epithelial polarization: loss of func-
tion in breast tumor cells. Cancer Res 2002, 62:7102-7109.
36. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ,
Petersen OW: Normal and tumor-derived myoepithelial cells
differ in their ability to interact with luminal breast epithelial
cells for polarity and basement membrane deposition. J Cell
Sci 2002, 115:39-50.
37. Ben-Hur H, Cohen O, Schneider D, Gyrevich P, Halperin R, Bala
U, Mozes M, Zusman I: The role of lymphocytes and
macrophages in human breast tumorigenesis: an immunohis-
tochemical and morphometric study. Anticancer Res 2002, 22:
1231-1238.
38. Gannot G, Gannot I, Vered H, Buchner A, Keisari Y: Increase in
immune cell infiltration with progression of oral epithelium
from hyperkeratosis to dysplasia and carcinoma. Br J Cancer
2002, 86:1444-1448.
39. Russo J, Ao X, Grill C, Russo IH: Pattern of distribution of cells
positive for estrogen receptor alpha and progesterone recep-
tor in relation to proliferating cells in the mammary gland.
Breast Cancer Res Treat 1999, 53:217-227.
40. Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK,
Clark GM, Allred DC: Estrogen receptor beta protein in human
breast cancer: correlation with clinical tumor parameters.
Cancer Res 2003, 63:2434-2439.
41. Malzahn K, Mitze M, Thoenes M, Moll R: Biological and prognos-
tic significance of stratified epithelial cytokeratins in infiltrat-
ing ductal breast carcinomas. Vir Arch 1998, 433:119-129.
42. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen, Ronnov-
Jessen L, Bissell MJ: The plasticity of human breast carcinoma
cells is more than epithelial to mesenchymal conversion.
Breast Cancer Res 2001, 3:213-217.
43. Petersen OW, Hoyer PE, van Deurs B. Frequency and distribu-
tion of estrogen receptor-positive cells in normal, nonlactating
human breast tissue. Cancer Res 1987, 47:5748-5751.
44. Chen CM, Martin LA, Johnston SR, Ali S, Dowsett M: Molecular
changes associated with the acquisition of oestrogen hyper-
sensitivity in MCF-7 breast cancer cells on long-term oestro-
gen deprivation. J Steroid Biochem Mol Biol 2002, 81:333-341.
45. Man YG, Mattu R, Zhang R, Yousefi M, Sang QXA, Shen T: A
subset of normal and hyperplastic appearing mammary
Breast Cancer Research    Vol 5 No 6 Man et al.
R240ductal cells display invasive features [abstract]. Breast Cancer
Res Treat 2003, in press.
46. Man YG, Zhang R, Mattu R, Shen T, Sang QXA: A subset of
mammary epithelial cells overlying focally disrupted myo-
epithelial cell layers shows an unusual immunostaining
pattern for proliferation-related proteins [abstract]. Breast
Cancer Res Treat 2003, in press.
47. Ponder BA: Cancer genetics. Nature 2001, 411:336-341.
Correspondence
Yan-gao Man, MD, PhD, Department of Gynecologic and Breast
Pathology, Armed Forces Institute of Pathology and American Registry
of Pathology, 6825 16th Street, NW, Washington, DC 20306-6000,
USA. Tel: +1 202 782 1612; fax: +1 202 782 3939; e-mail:
man@afip.osd.mil
Available online http://breast-cancer-research.com/content/5/6/R231
R241